Ferozsons Laboratories Past Earnings Performance
Past criteria checks 2/6
Ferozsons Laboratories has been growing earnings at an average annual rate of 12.9%, while the Pharmaceuticals industry saw earnings growing at 4.1% annually. Revenues have been growing at an average rate of 19.3% per year. Ferozsons Laboratories's return on equity is 5%, and it has net margins of 2.7%.
Key information
12.9%
Earnings growth rate
12.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 20.2% |
| Revenue growth rate | 19.3% |
| Return on equity | 5.0% |
| Net Margin | 2.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Ferozsons Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 14,516 | 395 | 3,854 | 0 |
| 30 Sep 23 | 13,319 | 408 | 3,591 | 0 |
| 30 Jun 23 | 11,457 | 271 | 3,205 | 0 |
| 31 Mar 23 | 10,743 | 164 | 3,185 | 0 |
| 31 Dec 22 | 10,173 | 409 | 3,045 | 0 |
| 30 Sep 22 | 9,674 | 587 | 2,835 | 0 |
| 30 Jun 22 | 9,330 | 734 | 2,651 | 0 |
| 31 Mar 22 | 9,788 | 1,263 | 2,556 | 0 |
| 31 Dec 21 | 9,582 | 1,265 | 2,414 | 0 |
| 30 Sep 21 | 9,593 | 1,330 | 2,236 | 0 |
| 30 Jun 21 | 8,879 | 1,173 | 2,085 | 0 |
| 31 Mar 21 | 7,619 | 917 | 1,730 | 0 |
| 31 Dec 20 | 7,049 | 737 | 1,680 | 0 |
| 30 Sep 20 | 6,385 | 456 | 1,724 | 0 |
| 30 Jun 20 | 6,212 | 417 | 1,705 | 0 |
| 31 Mar 20 | 6,374 | 335 | 1,866 | 0 |
| 31 Dec 19 | 6,000 | 248 | 1,865 | 0 |
| 30 Sep 19 | 5,926 | 207 | 1,779 | 0 |
| 30 Jun 19 | 5,803 | 201 | 1,718 | 0 |
| 31 Mar 19 | 5,249 | 77 | 1,614 | 0 |
| 31 Dec 18 | 5,162 | 83 | 1,593 | 0 |
| 30 Sep 18 | 5,180 | 16 | 1,549 | 0 |
| 30 Jun 18 | 5,003 | 7 | 1,480 | 0 |
| 31 Mar 18 | 5,111 | -32 | 1,489 | 0 |
| 31 Dec 17 | 4,836 | 213 | 1,383 | 0 |
| 30 Sep 17 | 4,707 | 244 | 1,327 | 0 |
| 30 Jun 17 | 5,002 | 396 | 1,340 | 0 |
| 31 Mar 17 | 5,667 | 669 | 1,450 | 0 |
| 31 Dec 16 | 7,494 | 917 | 1,507 | 0 |
| 30 Sep 16 | 9,602 | 1,675 | 1,572 | 0 |
| 30 Jun 16 | 11,295 | 2,204 | 1,547 | 0 |
| 31 Mar 16 | 11,390 | 2,343 | 1,411 | 0 |
| 31 Dec 15 | 10,113 | 2,121 | 1,308 | 0 |
| 30 Sep 15 | 7,860 | 1,528 | 1,218 | 0 |
| 30 Jun 15 | 5,711 | 905 | 1,177 | 0 |
| 31 Mar 15 | 4,689 | 697 | 1,141 | 0 |
| 31 Dec 14 | 4,051 | 573 | 1,115 | 0 |
| 30 Sep 14 | 3,825 | 542 | 1,072 | 0 |
| 30 Jun 14 | 3,832 | 526 | 1,038 | 0 |
| 31 Mar 14 | 3,640 | 579 | 940 | 0 |
| 31 Dec 13 | 3,379 | 505 | 912 | 0 |
| 30 Sep 13 | 3,171 | 469 | 883 | 0 |
| 30 Jun 13 | 2,879 | 455 | 843 | 0 |
Quality Earnings: FEROZ has high quality earnings.
Growing Profit Margin: FEROZ's current net profit margins (2.7%) are lower than last year (4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FEROZ's earnings have grown by 12.9% per year over the past 5 years.
Accelerating Growth: FEROZ's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: FEROZ had negative earnings growth (-3.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-3.3%).
Return on Equity
High ROE: FEROZ's Return on Equity (5%) is considered low.